Abstract
Chromogranin A (CgA), a major component of the chromaffin granules, is co-stored and co-released with catecholamines. It is also expressed in extra-adrenal sites, including the heart. In the rat, CgA localizes in atrial myoendocrine cells, associated with Atrial Natriuretic Peptide (ANP), and in the conduction system. In the human heart it is present in the ventricular myocardium, co-localized with B-type NP (BNP). CgA is the precursor of several biologically active peptides generated by proteolytic processing also in the heart. Two of them, vasostatin-1 (VS-1) and catestatin (Cst), inhibit cardiac contraction and relaxation, counter-regulate beta-adrenergic and endothelinergic stimulation, and protect the heart against ischemia/reperfusion damages. Recently, clinical studies have suggested CgA to be involved also in cardiovascular pathologies. High plasma CgA levels were found in hypertension, chronic and acute heart failure, myocardial infarction, decompensated and hypertrophic heart, and acute coronary syndromes. These alterations correlate with those of conventional cardiovascular biomarkers, such as NP and endothelin-1 (ET-1), and have prognostic relevance, being indicative of both severity of the disease and mortality. Accordingly, the current knowledge indicates CgA as a multifaceted peptide in cardiovascular homeostasis. Whether the influence elicited by the protein on both normal and failing heart is beneficial and/or detrimental, as well as its implication in the cardiac neuroendocrine scenario is under intense investigation. This review will focus on: i) the involvement of CgA and its derived peptides in the mechanisms which sustain cardiac function and compensation, ii) CgA clinical relevance, and iii) its putative value as a clinical biomarker.
Keywords: Chromogranin-A, Heart, Heart failure, Myocardial infarction, Acute coronary syndromes, hromaffin granules, catecholamines, Natriuretic Peptide, ventricular myocardium, beta-adrenergic.
Current Medicinal Chemistry
Title:Chromogranin-A: A Multifaceted Cardiovascular Role in Health and Disease
Volume: 19 Issue: 24
Author(s): T. Angelone, R. Mazza and M. C. Cerra
Affiliation:
Keywords: Chromogranin-A, Heart, Heart failure, Myocardial infarction, Acute coronary syndromes, hromaffin granules, catecholamines, Natriuretic Peptide, ventricular myocardium, beta-adrenergic.
Abstract: Chromogranin A (CgA), a major component of the chromaffin granules, is co-stored and co-released with catecholamines. It is also expressed in extra-adrenal sites, including the heart. In the rat, CgA localizes in atrial myoendocrine cells, associated with Atrial Natriuretic Peptide (ANP), and in the conduction system. In the human heart it is present in the ventricular myocardium, co-localized with B-type NP (BNP). CgA is the precursor of several biologically active peptides generated by proteolytic processing also in the heart. Two of them, vasostatin-1 (VS-1) and catestatin (Cst), inhibit cardiac contraction and relaxation, counter-regulate beta-adrenergic and endothelinergic stimulation, and protect the heart against ischemia/reperfusion damages. Recently, clinical studies have suggested CgA to be involved also in cardiovascular pathologies. High plasma CgA levels were found in hypertension, chronic and acute heart failure, myocardial infarction, decompensated and hypertrophic heart, and acute coronary syndromes. These alterations correlate with those of conventional cardiovascular biomarkers, such as NP and endothelin-1 (ET-1), and have prognostic relevance, being indicative of both severity of the disease and mortality. Accordingly, the current knowledge indicates CgA as a multifaceted peptide in cardiovascular homeostasis. Whether the influence elicited by the protein on both normal and failing heart is beneficial and/or detrimental, as well as its implication in the cardiac neuroendocrine scenario is under intense investigation. This review will focus on: i) the involvement of CgA and its derived peptides in the mechanisms which sustain cardiac function and compensation, ii) CgA clinical relevance, and iii) its putative value as a clinical biomarker.
Export Options
About this article
Cite this article as:
Angelone T., Mazza R. and C. Cerra M., Chromogranin-A: A Multifaceted Cardiovascular Role in Health and Disease, Current Medicinal Chemistry 2012; 19 (24) . https://dx.doi.org/10.2174/092986712802430009
DOI https://dx.doi.org/10.2174/092986712802430009 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects on Cytokines and Histology by Treatment with the Ace Inhibitor Captopril and the Antioxidant Retinoic Acid in the Monocrotaline Model of Experimentally Induced Lung Fibrosis
Current Pharmaceutical Design Recent Patents on Polymeric Scaffolds for Tissue Engineering
Recent Patents on Biomedical Engineering (Discontinued) Acute Ischemic Cerebrovascular Events on Antiplatelet Therapy: What is the Optimal Prevention Strategy?
Current Pharmaceutical Design Impact of Hyperhomocyst(e)inemia on Endothelial Function
Vascular Disease Prevention (Discontinued) Effect of Aglycon and Glycoside Flavonoid-Enriched Extracts Obtained from Buxus sempervirens L. on Glucose and Lipid Metabolism in Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Vigna unguiculata Trypsin Inhibitor: A Protein with Versatile Biological Applications
Current Enzyme Inhibition Clinical Research in India - Current Scenario and the Need of the Hour
Applied Clinical Research, Clinical Trials and Regulatory Affairs Calcium Channel Blockers in Obesity-Related Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Renin-Angiotensin System in Diabetes
Protein & Peptide Letters Arterial Stiffness: A Novel Cardiovascular Risk Factor in Kidney Disease Patients
Current Vascular Pharmacology Abstracts from Speakers
Cardiovascular & Hematological Disorders-Drug Targets Biological Active Peptides from Marine Sources Related to Gut Hormones
Current Protein & Peptide Science Therapeutic Effects of Rivastigmine and Alfa-Lipoic Acid Combination in the Charles Bonnet Syndrome: Electroencephalography Correlates
Current Clinical Pharmacology New Biotechnological Methods to Reduce Oxidative Stress in the Cardiovascular System: Focusing on the Bach1/Heme Oxygenase-1 Pathway
Current Pharmaceutical Biotechnology Systemic Therapies for Pancreatic Cancer - The Role of Pharmacogenetics
Current Drug Targets Editorial: Understanding Basic Muscle Electrophysiology While Keeping an Eye on Diseases of the Heart, Lung and Blood
Recent Patents on Cardiovascular Drug Discovery On Sports And Genes
Recent Patents on DNA & Gene Sequences A Newly Found Gasotransmitter, Hydrogen Sulfide, in the Pathogenesis of Hypertension and Other Cardiovascular Diseases
Current Hypertension Reviews Coumarins as Promising Scaffold for the Treatment of Age-related Diseases – An Overview of the Last Five Years
Current Topics in Medicinal Chemistry Infant Breast-Feeding and Suppression of Biomarkers of Future Cardiovascular Disease
Current Nutrition & Food Science